Scarica l'app Stockscreener
33.09
0.79%
0.26
Precedente Chiudi:
$32.83
Aprire:
$33.22
Volume 24 ore:
812.92K
Relative Volume:
0.91
Capitalizzazione di mercato:
$2.91B
Reddito:
$218.71M
Utile/perdita netta:
$-113.70M
Rapporto P/E:
-25.39
EPS:
-1.3034
Flusso di cassa netto:
$-73.47M
1 W Prestazione:
-0.30%
1M Prestazione:
+9.32%
6M Prestazione:
+34.46%
1 anno Prestazione:
+74.53%
Intervallo 1D:
$32.15
$34.02
Intervallo di 1 settimana:
$32.15
$35.50
Portata 52W:
$13.45
$39.28
Ideaya Biosciences Inc Stock (IDYA) Company Profile
Nome
Ideaya Biosciences Inc
Settore
Industria
Telefono
650-443-6209
Indirizzo
5000 SHORELINE CT, SUITE 300, SOUTH SAN FRANCISCO, CA
Compare IDYA vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IDYA
Ideaya Biosciences Inc
|
33.09 | 2.91B | 218.71M | -113.70M | -73.47M | -1.3034 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 119.23B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.84B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.35B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 41.57B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Ideaya Biosciences Inc Stock (IDYA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-07 | Ripresa | UBS | Buy |
| 2025-11-24 | Iniziato | Truist | Buy |
| 2025-09-18 | Iniziato | Guggenheim | Buy |
| 2025-09-04 | Iniziato | Barclays | Overweight |
| 2025-09-04 | Iniziato | Citizens JMP | Mkt Outperform |
| 2025-07-22 | Iniziato | TD Cowen | Buy |
| 2025-07-10 | Ripresa | Goldman | Neutral |
| 2025-06-26 | Iniziato | Wells Fargo | Overweight |
| 2024-11-18 | Iniziato | Stephens | Overweight |
| 2024-11-05 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2024-10-24 | Iniziato | UBS | Buy |
| 2024-10-15 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-07-08 | Iniziato | Mizuho | Outperform |
| 2024-03-08 | Iniziato | BTIG Research | Buy |
| 2023-08-08 | Iniziato | SVB Securities | Outperform |
| 2023-05-24 | Iniziato | Goldman | Buy |
| 2023-04-24 | Aggiornamento | Stifel | Hold → Buy |
| 2023-03-23 | Iniziato | Berenberg | Buy |
| 2023-02-28 | Iniziato | RBC Capital Mkts | Outperform |
| 2022-12-28 | Iniziato | CapitalOne | Overweight |
| 2022-10-27 | Iniziato | Citigroup | Buy |
| 2022-08-15 | Downgrade | Stifel | Buy → Hold |
| 2022-07-18 | Ripresa | Oppenheimer | Outperform |
| 2022-03-10 | Aggiornamento | Stifel | Hold → Buy |
| 2021-09-23 | Iniziato | Stifel | Hold |
| 2021-06-04 | Ripresa | Robert W. Baird | Outperform |
| 2021-03-11 | Iniziato | Guggenheim | Buy |
| 2020-10-07 | Iniziato | Wedbush | Outperform |
| 2020-09-01 | Iniziato | Northland Capital | Outperform |
| 2020-07-13 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2020-06-17 | Reiterato | H.C. Wainwright | Buy |
| 2020-04-06 | Iniziato | H.C. Wainwright | Buy |
| 2020-03-13 | Iniziato | ROTH Capital | Buy |
| 2019-10-17 | Iniziato | Oppenheimer | Outperform |
| 2019-09-10 | Iniziato | Robert W. Baird | Outperform |
| 2019-06-17 | Iniziato | Citigroup | Buy |
| 2019-06-17 | Iniziato | JP Morgan | Neutral |
| 2019-06-17 | Iniziato | Jefferies | Buy |
Mostra tutto
Ideaya Biosciences Inc Borsa (IDYA) Ultime notizie
IDEAYA Biosciences Experiences Revision in Stock Evaluation Amid Mixed Market Signals - Markets Mojo
42,283 Shares in IDEAYA Biosciences, Inc. $IDYA Bought by WINTON GROUP Ltd - MarketBeat
Truist reiterates Ideaya Biosciences stock rating on MTAP program By Investing.com - Investing.com Canada
IDEAYA Biosciences: Expanding Precision Oncology Platform and Refocused MTAP Strategy Support Buy Rating - TipRanks
Ideaya Biosciences announces first-patient-in for phase 1 trial of IDE892 - marketscreener.com
Ideaya Biosciences Announces First-Patient-In For Phase 1 Trial Of IDE892 - TradingView
IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE892, a Potential Best-In-Class PRMT5 Inhibitor for MTAP-Deleted Solid Tumors, and Provides MTAP and CDKN2A Pipeline Update - PR Newswire
IDEAYA Biosciences announces the latest development timeline for its Cdkn2a project - Bitget
(IDYA) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Goldman Sachs Maintains IDEAYA Biosciences (IDYA) Neutral Recommendation - MSN
IDEAYA Biosciences, Inc. (IDYA) Enrolls First Patient in Phase 1 Trial of IDE034 Bispecific ADC - finance.yahoo.com
Aug Mood: What is IDEAYA Biosciences Incs P E ratio telling usJuly 2025 Action & Fast Gain Stock Tips - baoquankhu1.vn
Fisher Asset Management LLC Lowers Stock Holdings in IDEAYA Biosciences, Inc. $IDYA - MarketBeat
IDYA Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
IDEAYA Biosciences (NASDAQ:IDYA) Shares Gap Up on Insider Buying Activity - MarketBeat
IDEAYA Biosciences, Inc. (IDYA) Stock Analysis: A Biotech Gem With 51% Upside Potential - DirectorsTalk Interviews
Did IDEAYA’s (IDYA) First-in-Human IDE034 Trial Just Redefine Its Targeted Oncology Strategy? - simplywall.st
Ideaya Biosciences Insider Bought Shares Worth $1,647,890, According to a Recent SEC Filing - marketscreener.com
Insider Buying: IDEAYA Biosciences (NASDAQ:IDYA) Director Buys 50,000 Shares of Stock - MarketBeat
Ideaya Biosciences (IDYA) director Stein buys $1.65 million in stock By Investing.com - Investing.com Australia
Ideaya Biosciences (IDYA) director Stein buys $1.65 million in stock - Investing.com
Director Jeffrey Stein buys 50,000 IDEAYA Biosciences (IDYA) shares in market - Stock Titan
IDEAYA Biosciences Director Jeffrey Stein Acquires 50,000 Shares - TradingView
IDEAYA Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update - The AI Journal
Biocytogen Announces Clinical Milestone with First Patient Dosed in Phase 1 Trial of IDEAYA’s First-in-Class B7H3/PTK7 Bispecific TOP1 ADC IDE034 - Via TT
Assessing IDEAYA Biosciences (IDYA) Valuation After IDE034 First-In-Human Dosing Milestone - Yahoo Finance
Biocytogen Announces Clinical Milestone with First Patient Dosed in Phase 1 Trial of IDEAYA's First-in-Class B7H3/PTK7 Bispecific TOP1 ADC IDE034 - lelezard.com
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GuruFocus
Fifth Lane Capital LP Invests $932,000 in IDEAYA Biosciences, Inc. $IDYA - MarketBeat
Ideaya Biosciences announces inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Ideaya Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Evaluating IDEAYA Biosciences (IDYA) Valuation As Recent Volatility Sends Mixed Signals - simplywall.st
IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE034, a Potential First-In-Class B7H3/PTK7 Bispecific Top1 ADC - marketscreener.com
(IDYA) Risk Channels and Responsive Allocation - Stock Traders Daily
Ideaya Biosciences announces first-patient-in for phase 1 trial of IDE034, a potential first-in-class B7h3/Ptk7 bispecific Top1 ADC - marketscreener.com
IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE034, a Potential First-In-Class B7H3/PTK7 Bispecific TOP1 ADC - The AI Journal
Ideaya Biosciences Announces First-Patient-In For Phase 1 Trial Of Ide034, A Potential First-In-Class B7h3/Ptk7 Bispecific Top1 Adc - TradingView
IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE034, a Potential First-In-Class B7H3/PTK7 Bispecific TOP1 ADC – Company Announcement - Financial Times
IDEAYA Biosciences, Inc. (IDYA) Stock Analysis: Unlocking A Potential 58% Upside - DirectorsTalk Interviews
Published on: 2026-02-25 12:19:59 - baoquankhu1.vn
Published on: 2026-02-24 09:21:42 - baoquankhu1.vn
IDEAYA Biosciences appoints Theodora Ross as development chief - Investing.com South Africa
IDEAYA Biosciences Teases Late-March Phase III Darovasertib Readout, ADC Updates, New KAT6/7 Phase I Launch - Yahoo Finance
IDYA: Darovasertib's phase 3 PFS readout is imminent, with accelerated approval filing expected this year - TradingView
IDEAYA Biosciences Teases End-of-March Data for Darovasertib Combo at Citi Oncology Summit - Yahoo Finance
Can IDEAYA Biosciences Inc reach all time highs this yearWeekly Stock Analysis & High Accuracy Trade Signal Alerts - baoquankhu1.vn
IDEAYA Biosciences Announces Appointment of Dr. Theodora (Theo) Ross, M.D., Ph.D., as Chief Development Officer - GuruFocus
Theodora Ross Joins Ideaya, Leaving Impact on AbbVie (ABBV) - GuruFocus
Ideaya Biosciences Announces Appointment Of Dr. Theodora (Theo) Ross, M.D., Ph.D., As Chief Development Officer - TradingView
IDEAYA Biosciences appoints Theodora Ross as development chief By Investing.com - Investing.com UK
IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Ideaya Biosciences Inc Azioni (IDYA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.48%
1.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):